PROFILE: EMA pharmacovigilance chief June Raine on how to improve risk management and inspiring women
This article was originally published in SRA
June Raine is the first ever chair of the European Medicines Agency's Pharmacovigilance Risk Assessment Committee, which oversees the risk management of your medicines. Dr Raine is also director of vigilance and risk management at MHRA, the UK regulator, as well as a member of the World Health Organization advisory committee on the safety of medicinal products. She talked to Francesca Bruce* about her passion for public health, preventing drug crises, and dancing to ABBA.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.